Bold Moves

Deliver first-in-class science

Lead the conversation

Pfizer is progressing a pipeline of potential first- or best-in-class treatments for nonalcoholic steatohepatitis (NASH) that could fill a significant unmet need for patients

The first time Roger Ortega learned about NASH was when he was admitted to the intensive care unit. The serious and progressive form of nonalcoholic fatty liver disease is caused by a buildup of fat in the liver and accompanied by inflammation, liver cell damage and in some cases, scarring of the liver. NASH significantly increases morbidity, is associated with a higher risk of cardiovascular and cerebrovascular events (such as heart attack or stroke) and is a leading cause for liver transplants in the U.S.1,2

Remembering Roger Ortega, one of the many NASH patients who inspire Pfizer


Sadly, Roger recently passed away. But his story endures – and echoes the experiences of so many others living with this condition. Despite its significant impact, NASH is largely unrecognized and underdiagnosed. Many patients may not receive a diagnosis until the disease is in an advanced stage, and there are currently no approved treatments for NASH.

18 million 

NASH affects approximately 3-5% of the global adult population, including an estimated 18 million adults in the U.S. alone.3,4,5

Today, Pfizer is building on its long history of discovering and developing therapies for cardiovascular and metabolic diseases and leveraging this expertise for patients like Roger, and in his words, “for generations to come.” We are rapidly progressing a robust pipeline of potential first- or best-in-class treatments for NASH, designed and developed in Pfizer’s laboratories. Our goal is to advance novel therapies that may slow and ultimately reverse the life-threatening downstream consequences of NASH – and positively impact the lives of millions of patients around the world.

Learn more about NASH and its burden and impact on patients and society


1Haldar, D., Kern, B., Hodson, J., Armstrong, M. J., Adam, R., Berlakovich, G., Fritz, J., Feurstein, B., Popp, W., Karam, V., Muiesan, P., O'Grady, J., Jamieson, N., Wigmore, S. J., Pirenne, J., Malek-Hosseini, S. A., Hidalgo, E., Tokat, Y., Paul, A., Pratschke, J., … Schneeberger S. (2019). Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study. Journal of Hepatology, 71(2), 313–322.

2U.S. Department of Health & Human Services. (2021, January 31). Data. Organ Procurement and Transplantation Network.

3Adapted model based on Estes, C., Anstee, Q. M., Arias-Loste, M. T., Bantel, H., Bellentani, S., Caballeria, J., Colombo, M., Craxi, A., Crespo, J., Day, C. P., Eguchi, Y., Geier, A., Kondili, L. A., Kroy, D. C., Lazarus, J. V., Loomba, R., Manns, M. P., Marchesini, G., Nakajima, A., Negro, F., … Razavi, H. (2018). Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. Journal of Hepatology, 69(4), 896–904.

4American Liver Foundation. (2019, November 11). NASH Definition & Prevalence. American Liver Foundation. 

5Sherif, Z. A., Saeed, A., Ghavimi, S., Nouraie, S. M., Laiyemo, A. O., Brim, H., & Ashktorab, H. (2016). Global Epidemiology of Nonalcoholic Fatty Liver Disease and Perspectives on US Minority Populations. Digestive Diseases and Sciences, 61(5), 1214–1225.​​​​​​​

Discover more

Advances for a Potential First-in-Class Chronic OA Pain Treatment

Advancing Breakthroughs for Patients With NASH

Eucrisa, Now Starring Jessica Simpson

Working for Patients with Alopecia Areata

Advancing a Potential Breakthrough for Moderate to Severe Atopic Dermatitis

A Potentially Practice-Changing Approval in Advanced Urothelial Cancer

Addressing an Unmet Need for Certain Patients With BRAF-Mutant mCRC

Learning From Early Breast Cancer Studies to Drive Oncology Research Forward

Cancer Doesn’t Wait: Supporting Screenings During COVID-19

Positive Phase 1/2 Data at One Year for Hemophilia A Gene Therapy

Investigational Gene Therapy for Duchenne Muscular Dystrophy Achieves Exciting Milestones in 2020

Pfizer Vaccines Pipeline Includes Six Late-Stage Candidates

Pfizer Vaccines Launches​​​​​​​ Global Centers of Excellence Network

Progressing Maternal Vaccination Against Respiratory Syncytial Virus

Pfizer Pledges $100 Million Into New AMR Industry Fund

Partnering with Wellcome to Combat AMR in Sub-Saharan Africa

Expanding Access in China Through Health Insurance Innovation

Pfizer Invests in Biotechnology Innovation through the Pfizer Breakthrough Growth Initiative

Hospital Donations for COVID-19 Response

Pfizer Partners with BioNTech to Advance & Supply COVID-19 Vaccine​​​​​​​

Delivering on the Promise of Biosimilars

Driving Diversity in Our Research and Development​​​​​​​

Site Feature: Puurs, Belgium 

PGS Ingenuity Solves COVID-19 Cold Chain Storage Challenge​​​​​​​

Pfizer and Gilead Sciences Agree to Manufacture and Supply Remdesivir​​​​​​​

Key Medicine Supply and Public Policy During COVID-19

Pfizer Stands with Science

Five-Point Plan for Unprecedented Collaboration

COVID-19 Updates

Read the latest information about Pfizer’s COVID-19 vaccine on



Join the Conversation

Additional Information

Useful Links

The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries.

Copyright © 2020-2021 Pfizer Inc.
All rights reserved

Explore our stories